Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
Earnings Data
Report Date
Oct 30, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0Last Year’s EPS
0.04Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in advancing their clinical and preclinical pipeline, particularly with positive results in the STAAR study for Fabry disease and progress in neurology and prion disease programs. Despite these advancements, challenges remain, including the need to secure additional funding and a Fabry commercialization partner. The sentiment is generally positive but tempered by financial uncertainties.Company Guidance
Positive Results from STAAR Study in Fabry Disease
The registrational Phase 1/2 STAAR study showed positive top-line results with a mean annualized eGFR slope of almost 2 at 52 weeks across 32 patients. The FDA agreed that this metric will serve as the primary basis of approval under the accelerated approval pathway.
Neurology Genomic Medicine Company Milestone
Sangamo initiated its first clinical site in the Phase 1/2 STAND study in chronic neuropathic pain, marking its transition to a clinical stage neurology genomic medicine company.
Prion Disease Program Advances
A productive meeting with the U.K.'s MHRA was held for the preclinical prion disease program, with a planned CTA submission as early as mid-2026.
Equity Offering Completed
Sangamo completed an equity offering expected to fund planned operations into the fourth quarter of 2025, bridging to an anticipated Fabry commercialization agreement.
SGMO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SGMO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $0.48 | $0.46 | -4.17% |
May 12, 2025 | $0.75 | $0.46 | -38.67% |
Mar 17, 2025 | $1.01 | $0.85 | -15.84% |
Nov 12, 2024 | $2.71 | $2.44 | -9.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sangamo Biosciences (SGMO) report earnings?
Sangamo Biosciences (SGMO) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).
What is Sangamo Biosciences (SGMO) earnings time?
Sangamo Biosciences (SGMO) earnings time is at Oct 30, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SGMO EPS forecast?
SGMO EPS forecast for the fiscal quarter 2025 (Q3) is 0.